Derivatives of hydantoins, thiohydantoins, pyrimidinediones and thioxopyrimidinones, their preparation processes and their use as medicaments

1. A method of treating a disorder selected from the group consisting of acromegaly, hypophyseal adenomas, endocrine gastroenteropancreatic tumors bleeding in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of a compound of the formula

in racemic or enantiomeric form,

R1 is selected from the group consisting of (C 1 -C 12 ) alkyl, (C 0 -C 6 )alkyl-C(O)—O-Z1, (C 0 -C 6 )alkyl-C(O)—NH—(CH 2 ) p -Z 2 and unsubstituted or substituted aryl,

Z1 is selected from the group consisting of H, (C 1 -C 6 )alkyl and —(CH 2 ) p -aryl;

Z2 is selected from the group consisting of amino, (C 1 -C 12 )alkylamino, (C 3 -C 8 )cycloalkylamino, N,N-di-(C 1 -C 12 ) alkylamino,

NH—C—(O)—O—(CH 2 ) p -phenyl, NH—C(O)—O—(CH 2 ) p —(C 1 -C 6 )alkyl, phenyl, naphthyl, pyridinyl, furanyl, pyrrolyl, thiophenyl, thiazolyl, indanyl, indolyl, imidazolyl, benzofuranyl, benzothiophenyl and phthalimidyl, carbocyclic aralkyl selected from the group consisting of benzyl, phenylpropyl and phenylbutyl and heterocyclic aralkyl selected from the group consisting of indolylalkyl and phthalimidoalkyl and unsubstituted or substituted heterocyclic non-aromatic;

R2 is selected from the group consisting of H, (C 1 -C 12 ) alkyl and aryl optionally substituted;

R3 is H or(CH 2 ) p -Z3;

Z3 is selected from the group consisting of (C 1 -C 12 )alkyl, (C 1 -C 12 )alkenyl, (C 3 -C 8 ) cycloalkyl, Y1-(CH 2 ) p -phenyl-(X1) n , —S—(C 1 -C 12 )alkyl, S—(C 1 -C 12 )alkyl-S—S—(C 1 -C 12 ) alkyl, and unsubstituted or substituted carbocyclic or heterocyclic aryl;

bis-arylalkyl or

Y1 is O, S, NH or is absent;

R4 is (CH 2 ) p -Z4;

Z4 is selected from the group consisting of amino, (C 1 -C 12 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 12 )alkylamino, N,N-di-(C 1 -C 12 )alkylamino, amino (C 3 -C 6 ) cycloalkyl, amino (C 1 -C 6 ) alkyl (C 3 -C 8 ) cycloalkyl (C 1 -C 6 ) alkyl, carbocyclic or heterocyclic aminoaryl, (C 1 -C 12 ) alkoxy, (C 1 -C 12 ) alkenyl, N—C(O)O(C 1 -C 6 ) alkyl, unsubstituted or substituted carbocyclic or heterocyclic aryl, unsubstituted or substituted heterocyclic non-aromatic radical, bis-arylalkyl, di-arylalkyl,

and N (R6)(R7), R6 and R7 taken togetber with the nitrogen atom which they carry form together a heterocycle of 5 to 7 ring members;

R5 is selected from the group consisting of H, —(CH 2 ) p —C(O)—(CH 2 ) p -Z5, —(CH 2 ) p -Z5, —(CH 2 ) p —OZ5 or —(C 0 -C 6 )alkyl-C(O)—NH—(CH 2 ) p -Z5,

Z5 is unsubstituted or substituted member selected from the group consisting of —(C 1 -C 12 ) alkyl, benzo[b]thiophene, phenyl, naphthyl, benzo[b]furanyl, thiophene, isoxazolyl, indolyl,

it being understood that the above substitutes of Z5 are selected from the group consisting of Cl, F, Br, I, CF 3 , NO 2 , OH, NH 2 , CN, N 3 , —OCF 3 , (C 1 -C 12 ) alkyl, (C 1 -C 12 ) alkoxy, —(CH 2 ) p -phenyl-(X 1 ) q , —NH—CO—(C 1 -C 6 ) alkyl, —NH—C(O)O—(C 1 -C 6 ) alkyl, —S—(C 1 -C 6 ) alkyl, —S-phenyl-(X1) q , —O—(CH 2 ) p -phenyl-(X1) q , —(CH 2 ) p —C(O)—O—(C 1 -C 6 ) alkyl, —(CH 2 ) p —C(O)—(C 1 -C 6 ) alkyl, —O—(CH 2 ) p —NH 2 , —O—(CH 2 ) p —NH—(C 1 -C 6 ) alkyl, —O—(CH 2 ) p —N-di((C 1 -C 6 ) alkyl) and (C 0 -C 12 ) alkyl-(X1) q ;

X1, each time that it occurs, is independently selected from the group consisting of H, Cl, F, Br, I, CF 3 , NO 2 , OH, NH 2 , CN, N 3 , —OCF 3 , (C 1 -C 12 ) alkyl, (C 1 -C 12 ) alkoxy, —S—(C 1 -C 6 ) alkyl, —(CH 2 ) p -amino, —(CH 2 ) p —NH—(C 1 -C 6 ) alkyl, —(CH 2 ) p —N-di-((C 1 -C 6 ) alkyl, —(CH 2 ) p -phenyl and —(CH 2 ) p —NH—(C 3 -C 6 )-cycloalkyl;

p each time that it occurs is independently an integer from 0 to 6;

q each time that it occurs is independently an integer from 1 to 5;

X is O or S;

n in the chemical structure is 0;

n in Z3 is 0; and

m is 1, 2 or 3;

or a pharmaceutically acceptable salt of said compound sufficient to treat said disorder.

2. The method of claim 1 , wherein

R1 is unsubstituted or substituted aryl;

R2 is H or alkyl;

R3 is selected from the group consisting of

R4 is selected from the group consisting of

R5 is H or alkyl;

or a pharmaceutically acceptable salt of said compound.

3. The method of claim 1 , wherein

R1 is unsubstituted phenyl or phenyl substituted with a member of the group consisting of halogen, (C 1 -C 12 ) alkyl, (C 1 -C 12 ) alkoxy and nitro;

R2 and R5 are H or alkyl;

R3 is H or (CH 2 ) p -Z3;

Z3 is selected from the group consisting of (C 1 -C 12 ) alkyl, (C 3 -C 8 ) cycloalkyl, Y1-(CH 2 ) p -phenyl-(X1) n , unsubstituted or substituted carbocyclic or heterocyclic aryl, unsubstituted or substituted non-aromatic heterocyclic, bis-arylalkyl, di-arylalkyl,

Y1 represents O, S, NH or is absent;

R4 is (CH 2 ) p -Z4;

Z4 is selected from the group consisting of amino, (C 1 -C 12 ) alkyl, (C 3 -C 8 ) cycloalkyl, (C 1 -C 12 ) alkylamino, N,N-di-(C 1 -C 12 ) alkylamino, amino (C 3 -C 6 ) cycloalkyl, amino (C 1 -C 6 ) alkyl (C 3 -C 8 ) cycloalkyl (C 1 -C 6 ) alkyl, carbocyclic or heterocyclic aminoaryl , an unsubstituted or substituted carbocyclic and heterocyclic aryl, unsubstituted or substituted non-aromatic heterocyclic, bis-arylalkyl, di-arylalkyl,

it being understood that the substituent of substituted phenyl is at least one member of the group consisting of Cl, F, Br, I, CF 3 , NO 2 , OH, NH 2 , CN, N 3 , —OCF 3 , (C 1 -C 12 ) alkoxy, —(CH 2 ) p -phenyl-(X1) q , —NH—CO—(C 1 -C 6 ) alkyl, —NH—C(O)—(C 1 -C 6 ) alkyl, —S—(C 1 C 6 ) alkyl, —S-phenyl-(X1) q , —O—(CH 2 ) p -phenyl-(X1) q , —(CH 2 ) p —C(O)—O—(C 1 -C 6 ) alkyl, —(CH 2 ) p —C(O)—(C 1 -C 6 ) alkyl, —O—(CH 2 ) p —NH 2 , —O(CH 2 ) p —NH —(C 1 -C 6 )alkyl, —O—(CH 2 ) p —N-di-((C 1 - 6 ) alkyl and (C 0 -C 12 ) alkyl-(X1) q ;

X1, each time that it occurs, is selected from the group consisting of H, Cl, F, Br, I, CF 3 , NO 2 , OH, NH 2 , CN, N 3 , —OCF 3 , (C 1 -C 12 ) alkyl, (C 1 -C 12 ) alkoxy, —S—(C 1 -C 6 ) alkyl, —(CH 2 ) p -amino, —(CH 2 ) p —NH—(C 1 -C 6 ) alkyl, —(CH 2 ) p —N-di-((C 1 -C 6 ) alkyl), —(CH 2 ) p -phenyl and —(CH 2 ) p —NH—(C 3 -C 6 ) cycloalkyl;

p each time that it occurs is independently an integer from 0 to 6; and

q each lime that it occurs is independently an integer from 1 to 5.

4. The method of claim 3 , wherein

R1 is phenyl or phenyl substituted by a member selected from the group consisting of halogen, (C 1 -C 12 ) alkyl, (C 1 -C 12 ) alkoxy and nitro;

R2 and R5 are H or alkyl;

R3 is (C 2 ) p -Z3,

Z3 is selected from the group Z3 is selected from the group consisting of (C 3 -C 8 ) cycloalkyl, unsubstituted or substituted phenyl, naphthyl, furanyl, thiophene, indolyl, pyrrolyl and benzothiophene;

R4 is (CH 2 ) p -Z4;

Z4 is selected from the group consisting of amino, (C 1 -C 12 ) alkylamino, N,N-di-(C 1 -C 12 ) alkylamino and amino (C 1 -C 6 ) alkyl (C 3 -C 6 ) cycloalkyl-(C 1 -C 6 ) alkyl;

X is S;

p each time that it occurs is independently an integer from 0 to 6;

n is 0; and

m is 1, 2 or 3.

5. The method of claim 4 selected from the compounds of formulae

wherein R′3 is selected from

and R′3 is selected from

or a pharmaceutically acceptable salt or said compound.